Johannes Holtschmidt

4PUBLICATIONS
56CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|May 18, 2026
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

|Feb 25, 2025
Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study.

Peter A Fasching, Sabine Schmatloch, Jan Hauke

|Jan 30, 2025
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer.

Fabio Conforti, Valentina Nekljudova, Isabella Sala

|Jun 05, 2024
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials.

Paul Jank, Thomas Karn, Marion van Mackelenbergh

Pageof 1

Frequent Collaborators

3 joint publications

Michael Untch

3 joint publications

Sibylle Loibl

3 joint publications

Peter Fasching

3 joint publications

Carsten Denkert